综合基因组分析对临床试验入学的临床价值,对于患有晚期固体瘤的患者
Richard S P Huang1, Jessica K Lee1, Katherine T Lofgren1
1Foundation Medicine, Inc., Cambridge, MA, United States.
The oncologist
|October 29, 2024
概括
综合基因组分析 (CGP) 改善了晚期癌症的临床试验入学率. 这种生物标志物测试提供了基因组结果,使患者在临床试验中的参与率增加了3.0个百分点.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床试验 临床试验
背景情况:
- 生物标志物测试是癌症治疗决策的标准.
- 基因组测试结果并不总是可用于指导治疗.
- 在获取患者护理的基因组信息方面存在变化.
研究的目的:
- 评估综合基因组分析 (CGP) 对临床试验招生的影响.
- 分析CGP在晚期非小细胞肺癌,结肠直肠癌,乳腺癌和前列腺癌中的作用.
- 确定CGP报告的可用性和参与试验之间的关联.
主要方法:
- 利用现实世界的临床基因组数据库.
- 分析了患有晚期癌症的患者.
- 在CGP报告收到之前和之后的临床试验入学率的比较.
主要成果:
- 在CGP后的平均临床试验入学率为5.4%.
- 这与CGP前入学人数相比增加了3.0个百分点.
- 在CGP报告的可用性和增加的试验招生之间发现了显著的关联.
结论:
- 综合性基因组分析与更高的临床试验招生率有关.
- 通过临床试验,CGP的可用性可以促进患者通过临床试验获得向疗法.
- 现实数据支持CGP在促进癌症护理和参与研究方面的作用.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


